A Look at Upcoming Gastrointestinal Oncology Clinical Trials

 

 

Two new clinical trials - one treating pancreatic cancer and one treating Hepatocellular Carcinoma - are planned to open at UNC this fall.

 

The first clinical trial is a Phase II/III multi-center, randomized, controlled study for patients with previously untreated metastatic pancreatic cancer. This study compares the effectiveness of the standard agent gemcitabine alone to the combination of gemcitabine plus ON1910.Na. ON1910.Na is a novel oral agent that targets multiple activated oncogenes including Polo-like kinase, PI3 kinase and AKT. 

 

The second trial is a study of first line therapy for patients with Hepatocellular Carcinoma. This is a dose-finding and efficacy study of a novel inhibitor of the cMet growth factor in addition to standard sorafenib (Nexavar) therapy. UNC is one of four sites participating in this trial, and is the lead site for the trial.

 

For more information on these trials, call the protocol office at 919-966-4432.

 

 

 

 

Oncology nutritionist Jennifer Spring, RD, LDN, reviews a diet plan with a patient.

 

 

Welcome to New Faculty Member Autumn McRee, MD

 

 

Dr. McRee, an assistant professor of medicine, has joined the Gastrointestinal Oncology program upon completion of a hematology/oncology fellowship at UNC-Chapel Hill.

 

Prior to her fellowship, she completed a residency at Vanderbilt University in Nashville, Tennessee.

 

She received her medical degree from the University of Texas Health Science Center in Houston, Texas and her undergraduate degree in molecular biology from Vanderbilt University in Nashville, Tennessee.

 

 

New Gastrointestinal Oncology Clinical Trials Available Now

  • CALGB 80702 is a phase III study for patients with resected stage III colon cancer. The study is assessing the number of treatments (6 versus 12) of Adjuvant Folfox Plus Celecoxib or placebo.
  • LCCC 1029 is a UNC-led study with sites across the southeast for patients with KRAS-mutant metastatic colorectal cancer that has progressed after first-line treatment. This is the first study with regorafenib, and the first randomized study of kinase inhibition in combination with chemotherapy to focus on patients with K-RAS and BRAF genetic mutations whose options are limited after their disease progresses on initial treatment.

 

Contact Information

 

To refer a patient to UNC's Gastrointestinal Oncology program, call 919-966-9700.

 

For more information about Gastrointestinal Oncology clinical trials at UNC, call the protocol office at 919-966-4432.

UNC Lineberger    N.C. Cancer Hospital    Clinical Trials     Clinical Programs    Comprehensive Cancer Support

 

For questions about all clinical trials at UNC (including those at UNC that are also offered at other sites), contact the UNC Lineberger protocol office at 919-966-4432 or (toll-free) 1-877-668-0683.

 

To make an appointment at the N.C. Cancer Hospital for one of your patients, visit our web page for referring physicians. You may also contact the Carolina Consultation Center at 1-800-862-6264.